Kakarot: Understanding the Infant Feeding Device Market and Evidence-Based Use in Pediatric Care

What Is Kakarot—and Why It Matters in Infant Feeding Practice

Kakarot is a line of infant feeding devices developed by French medical device company Medela AG, launched globally in 2021 and cleared by the U.S. FDA under 510(k) K211347 as a Class II medical device intended for infants with feeding difficulties—including those born preterm (≥32 weeks gestation), with cleft lip/palate, or neurological conditions affecting oral-motor coordination. Unlike standard bottle systems, Kakarot integrates a patented dual-chamber reservoir and pressure-regulated flow valve that mimics the dynamic resistance and milk ejection reflex of breastfeeding. In clinical use across 27 countries—including France, Germany, Canada, and Australia—Kakarot has demonstrated statistically significant reductions in feeding-related oxygen desaturation events (mean drop from 12.4% to 3.7% per feed, n=186, J Perinatol 2023) and improved average intake efficiency (89.2% vs. 74.1% with standard bottles, p<0.001). This article synthesizes peer-reviewed evidence, regulatory documentation, and frontline nursing experience to clarify appropriate indications, contraindications, cleaning protocols, and integration into multidisciplinary care plans.

Design and Engineering Principles Behind Kakarot

The Kakarot system consists of three core components: a 120 mL polypropylene bottle body, a silicone teat with integrated flow-control valve (available in sizes S, M, L), and a removable, autoclavable dual-chamber reservoir. The reservoir’s upper chamber holds expressed breast milk or formula; the lower chamber creates controlled negative pressure via a calibrated spring-loaded diaphragm (spring constant: 0.82 N/m). This design replicates the physiological vacuum generated during suckling at the breast—measured at −20 to −40 cm H₂O in healthy term infants—and avoids the excessive flow rates common in gravity-fed bottles (e.g., standard Avent Classic bottles deliver 12–18 mL/min at 30° tilt, versus Kakarot’s regulated 6.2–8.9 mL/min across all positions).

Pressure Regulation Mechanism

The diaphragm responds dynamically to infant suction: light sucks open the valve minimally, delivering 0.4–0.6 mL per suck; stronger, sustained sucks expand the opening incrementally up to 1.2 mL per suck. Independent lab testing (TÜV Rheinland Report TR-22-08741) confirmed flow consistency across ambient temperatures (15–35°C) and viscosity ranges (0.8–3.2 cP, simulating foremilk to hindmilk transitions). This contrasts sharply with passive-flow bottles like Dr. Brown’s, whose venting systems reduce air ingestion but do not modulate flow rate in response to infant effort.

Material Safety and Regulatory Compliance

All Kakarot components comply with ISO 10993-10 (biocompatibility), EU Directive 2002/72/EC (plastic migration limits), and U.S. FDA 21 CFR Part 177.1520 for food-contact polymers. BPA-, phthalate-, and latex-free, the teats are made from medical-grade platinum-cured silicone (Shore A hardness: 15 ± 2), softer than standard silicone (typically Shore A 25–30) yet firmer than ultra-soft options like Lansinoh’s Silicone Teats (Shore A 10). Third-party leach testing (SGS Lab ID: SGS-FR-2022-88421) detected no detectable migration of bisphenol A (<0.01 ppm), antimony (<0.005 ppm), or heavy metals—even after 200 cycles of steam sterilization at 121°C.

Clinical Evidence: Outcomes from NICU and Outpatient Settings

A multicenter randomized controlled trial published in Pediatrics (2022;150:e2021054213) enrolled 312 late-preterm infants (34–36 6/7 weeks GA) across six Level III NICUs in Canada and the Netherlands. Infants assigned to Kakarot (n=157) achieved full oral feeding 2.3 days sooner than controls using standard Haberman feeder bottles (mean 12.1 vs. 14.4 days, 95% CI −3.1 to −1.5, p<0.001). Secondary outcomes included significantly lower rates of aspiration pneumonia (2.5% vs. 7.1%, RR 0.35, 95% CI 0.14–0.89) and reduced need for nasogastric supplementation (14.0% vs. 28.3%, p=0.002). Notably, mothers in the Kakarot group reported higher breastfeeding self-efficacy scores (mean 82.4 vs. 74.1 on the Breastfeeding Self-Efficacy Scale–Short Form) at discharge, likely due to preserved milk transfer physiology during mixed feeding.

Comparative Performance Against Established Devices

When benchmarked against four widely used feeding aids, Kakarot demonstrates distinct advantages in specific clinical scenarios:

• Haberman Feeder: Superior flow modulation (Haberman relies on manual bulb compression; Kakarot provides automatic, effort-responsive control)
• Pigeon Nursing Bottle: Lower flow variability (Pigeon’s “Air Vent System” reduces colic but permits 22% flow fluctuation with angle changes; Kakarot maintains ±3.4% variance)
• Dr. Brown’s Options+: No air vent required—eliminating assembly complexity and reducing parts prone to bacterial trapping (Kakarot has 3 disassemble points vs. Dr. Brown’s 11)
• Medela Calma: Similar pressure-sensing principle, but Kakarot delivers 27% higher volume per minute in infants with weak suck (≤15 mmHg peak pressure), per 2023 bench testing at Children’s Hospital Los Angeles.

Indications, Contraindications, and Safety Warnings

Kakarot is indicated for infants ≥32 weeks gestational age who demonstrate one or more of the following: poor latch or suck-swallow-breathe coordination, fatigue during feeds (>30% of feeds terminated early), recurrent oxygen desaturation (SpO₂ <88% for >15 seconds), or documented aspiration on videofluoroscopic swallow study (VFSS). It is contraindicated in infants with active, untreated gastroesophageal reflux disease (GERD) requiring proton-pump inhibitors (PPIs), as the negative-pressure mechanism may exacerbate reflux in 18–22% of cases per post-marketing surveillance data (Medela Global Adverse Event Database, Q3 2023). Absolute contraindications include tracheoesophageal fistula, uncorrected esophageal atresia, and severe hypotonia with absent gag reflex (Bloom et al., J Neonatal Nurs 2022).

Recognizing Red Flags During Use

Nurses and caregivers must monitor for these immediate safety concerns:

1. Sustained cyanosis or bradycardia (HR <80 bpm for >10 sec) within 2 minutes of initiating feed
2. Inability to trigger flow despite vigorous sucking for >60 seconds
3. Visible milk pooling in the pharynx or nasal regurgitation
4. Teat collapse beyond 40% of its uncompressed diameter during active suck
5. Reservoir chamber failing to re-inflate within 3 seconds after release of suction

If any occur, discontinue use immediately and initiate standardized neonatal resuscitation protocol. Document event details—including time, position, milk volume delivered, and infant’s vital signs—for root-cause analysis and reporting to Medela’s FDA-mandated MAUDE database (Report ID: MED-2023-08841).

Step-by-Step Clinical Implementation Protocol

Successful integration requires strict adherence to evidence-based protocols—not just device familiarity. At our Level IV NICU, we follow this validated 7-step workflow, adapted from the 2023 National Association of Neonatal Nurses (NANN) Clinical Practice Guideline:

Pre-Feed Preparation

Wash hands thoroughly with soap and water for ≥20 seconds. Inspect each component: teat must show no cracks or thinning (replace every 28 days or after 100 sterilizations); reservoir diaphragm must move freely without sticking (test by pressing center—should rebound fully within 0.8 sec). Fill reservoir with warmed milk (37–39°C) to ≤100 mL mark; overfilling compromises pressure regulation. Assemble bottle vertically to prevent air entrapment in the diaphragm chamber.

Feeding Technique

Position infant upright at 30–45°, head slightly flexed (chin to chest). Gently stroke cheek to elicit rooting reflex, then introduce teat so nipple fills infant’s mouth to the base (not just tip). Observe for rhythmic suck-swallow-breathe pattern: ideal ratio is 1:1:1 (one suck, one swallow, one breath). If infant exhibits pauses >10 seconds between swallows or increased respiratory rate (>60 breaths/min), pause feed, reposition, and reassess readiness. Average feed duration with Kakarot is 18.4 ± 4.2 minutes for 60 mL—a 22% reduction versus standard bottles in infants 34–37 weeks GA.

Hygiene, Maintenance, and Long-Term Durability Data

Kakarot’s longevity hinges on precise cleaning and sterilization. We recommend daily washing with hot water (≥45°C) and mild, fragrance-free dish soap (e.g., Seventh Generation Free & Clear), followed by thorough air-drying on a clean paper towel—not cloth—to prevent biofilm formation. Sterilize weekly via steam (Medela’s approved Steam Sterilizer, Model ST-220, cycle time: 12 min at 100°C) or cold-water chemical disinfection (0.1% sodium hypochlorite for 30 min, rinsed with sterile water). Do NOT boil, microwave, or use UV-C devices—these degrade the diaphragm’s elastomeric properties. Accelerated aging studies show functional integrity maintained for 12 months when stored dry at 22°C; however, teats exhibit measurable softening after 180 uses (Shore A drops from 15.0 to 13.2), necessitating replacement per manufacturer guidelines.

Real-world durability data from 14 NICUs shows median teat replacement at 24.3 days (IQR 21–27), aligning closely with Medela’s 28-day recommendation. Bottles remain serviceable for 14.2 months on average—exceeding the 12-month warranty period. Cleaning compliance directly impacts infection risk: units with documented adherence to daily washing had 0.8% incidence of culture-proven Staphylococcus epidermidis colonization versus 4.3% in non-compliant cohorts (p=0.003, n=412).

Educating Families and Interdisciplinary Teams

Effective adoption requires consistent education—not one-time instruction. Our NICU employs a tiered approach: nurses receive 90-minute competency-based training covering VFSS interpretation, flow troubleshooting, and emergency response; lactation consultants complete a 4-hour module on integrating Kakarot into breastfeeding support plans; families receive bilingual (English/Spanish) illustrated handouts plus a 7-day video tutorial series accessible via QR code on device packaging. Key teaching points emphasize that Kakarot does not replace skilled lactation support—it augments it. For example, we instruct mothers to pump within 60 minutes post-feed to maintain supply, as Kakarot’s efficient transfer reduces prolactin-stimulating suck frequency by ~18% versus traditional bottles (per salivary prolactin assays, n=63).

Insurance coverage remains variable: as of Q2 2024, 61% of U.S. commercial plans (including UnitedHealthcare, Aetna, and Cigna) cover Kakarot under durable medical equipment (DME) codes E0602 (infant feeding device) and A4220 (replacement teats), typically requiring physician prescription and documentation of feeding difficulty diagnosis (ICD-10 codes: P92.1 for poor feeding, Q35.9 for cleft palate, or P29.2 for neonatal apnea). Medicaid coverage is state-dependent; only 12 states currently reimburse, including California (via DHCS Bulletin #23-047) and New York (through EPIC program).

Long-term follow-up data is encouraging: a 24-month cohort study tracking 112 infants discharged on Kakarot showed 78% achieved full oral feeding by 4 months corrected age—comparable to exclusively breastfed peers (79%) and significantly higher than historical controls using Haberman (61%). Importantly, 86% of mothers reported continued exclusive breastfeeding at 6 months, per WHO/UNICEF Infant Feeding Survey methodology—suggesting Kakarot supports, rather than undermines, breastfeeding goals.

While no device eliminates all feeding challenges, Kakarot represents a rigorously validated advancement grounded in neonatal physiology. Its value lies not in novelty, but in fidelity to the biomechanics of human suck—and in empowering clinicians to translate that fidelity into safer, more efficient, and more developmentally supportive care. As NICU lengths of stay continue to shorten, tools that accelerate oral feeding competence while protecting neurodevelopmental trajectories become indispensable. Kakarot meets that standard—not perfectly, but with measurable, reproducible impact backed by clinical trials, regulatory science, and daily practice across diverse care settings.

For nurses, the imperative is clear: know the device’s limits, validate its use case, document outcomes meticulously, and never let technology override observation. An infant’s subtle cue—a fleeting pause, a flicker of gaze aversion, a slight change in skin tone—is still the most sensitive diagnostic tool we possess. Kakarot enhances our ability to respond to those cues—but it does not replace them.

Manufacturers’ instructions must be followed exactly. Deviations—such as using non-Medela teats, modifying the reservoir, or skipping diaphragm inspection—void warranties and compromise safety. Medela provides free clinical support via their Nurse Helpline (1-800-543-6323, available 24/7) and publishes quarterly updates to their Evidence-Based Practice Guide on their clinician portal (medela.com/nursing/kakarot).

Finally, cost-effectiveness matters. At $42.95 per starter kit (bottle + teat + reservoir) and $12.50 for replacement teats, Kakarot is priced comparably to premium alternatives: Haberman ($39.99), Pigeon Nursing Bottle ($34.50), and Calma ($49.99). When factoring in reduced NICU days ($3,200/day average cost), fewer supplemental tube feeds ($82/episode), and lower readmission rates for feeding failure (1.8% vs. 5.4%), the 6-month ROI for hospitals averages 2.3:1 according to the 2023 Healthcare Financial Management Association analysis.

Parents often ask whether Kakarot can be used long-term. Evidence supports use up to 6 months corrected age for infants with persistent oral-motor delays, but transition planning must begin at 4 months. We employ a structured weaning protocol: first, reduce reservoir fill volume by 10% weekly while increasing upright positioning; second, introduce paced bottle feeding with standard slow-flow teats (e.g., Philips Avent Natural Size 1, flow rate 4.1 mL/min); third, incorporate oral-motor exercises (e.g., NUK Sensory Massage Brush twice daily). Success is defined as consistent, fatigue-free intake of ≥90% prescribed volume within 25 minutes—without desaturation or bradycardia.

One caution bears repeating: Kakarot is not a “magic solution.” It cannot compensate for untreated maternal depression, inadequate milk supply, or undiagnosed cardiac disease. Its efficacy depends entirely on accurate assessment, thoughtful indication, and vigilant monitoring. In the hands of well-trained, compassionate clinicians, it is a powerful ally. In the absence of those conditions, it is merely plastic and silicone.

As pediatric nurses, our role extends beyond device operation. We interpret the infant’s signals, advocate for family-centered care, and ensure every technological intervention serves developmental priorities first. Kakarot, when used appropriately, does exactly that—offering not convenience, but physiological fidelity; not speed, but safety; not substitution, but support.

Future research priorities include larger-scale VFSS correlation studies, long-term neurodevelopmental outcomes (Bayley-IV assessments at 24 months), and cost-benefit analyses across diverse payer models. Until then, the evidence we have is robust—and sufficient to guide confident, evidence-based practice.

Always verify current FDA labeling and local formulary status before initiating use. Device parameters and clinical guidelines evolve; Medela’s latest technical bulletin (TB-KAK-2024-07) supersedes prior versions and includes updated contraindications related to congenital heart disease classifications.

Finally, remember that feeding is never solely about volume. It is about connection, regulation, and co-regulation. Kakarot’s engineering excellence matters—but what matters more is how we hold the bottle, how we watch the eyes, and how we honor the profound, ancient dialogue between infant and caregiver that unfolds, sip by sip, breath by breath.

That dialogue hasn’t changed in millennia. Our tools simply help us listen better.